Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681623 · ClinicalTrials.gov registry record
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
A clinical trial of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, sponsored by Neurology Center of New England P.C..
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06681623: Recruiting study of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, sponsored by Neurology Center of New England P.C..
NCT06681623 is a study of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis that is actively recruiting participants, run by Neurology Center of New England P.C.. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06681623, a study of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, is actively recruiting participants, sponsored by Neurology Center of New England P.C..
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Primary Outcome
Incidence of infection rate from Baseline to Month 24/End of Study
Conditions Studied
Interventions
- DRUG Ublituximab
Study Locations (1)
Massachusetts
- Neurology Center of New England P.C. - Foxborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-09-30 |
What NCT06681623 shows while recruiting
NCT06681623 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT06681623 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06681623 about?
NCT06681623 is a clinical study titled "A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)". The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
What is the current status of trial NCT06681623?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-08-13. Estimated completion is 2027-09-30.
What conditions does trial NCT06681623 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis.
What interventions are being tested in trial NCT06681623?
The interventions under investigation include: Ublituximab (DRUG).
Who is sponsoring clinical trial NCT06681623?
This trial is sponsored by Neurology Center of New England P.C., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06681623 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI